Sort   by:  
 Page size 
TranscriptomicsComparative transcriptome profiling of Amyloid Precursor Protein APP family members in the adult cortex
The β-amyloid precursor protein APP and the related APLPs, undergo complex proteolytic processing giving rise to several fragments. Whereas it is well established that Aβ accumulation is a central trigger for Alzheimer disease (AD), the physiological role of APP family members and their diverse pr...
ORGANISM(S): Mus musculus 
2011-03-18 | E-GEOD-25926 | biostudies-arrayexpress
TranscriptomicsComparative transcriptome analysis of APPs?-DM and APLP2-KO brains
Despite its key role in Alzheimer pathogenesis, the physiological function(s) of the amyloid precursor protein (APP) and of its proteolytic fragments are still poorly understood. The secreted APPs? ectodomain has been shown to be involved in neuroprotection and synaptic plasticity. The ?-secretase g...
ORGANISM(S): Mus musculus 
2011-05-10 | E-GEOD-27888 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of mouse vehicle and sAPPalpha-treated hippocampal slice cultures
Gene expression changes induced by alpha-secretase cleaved amyloid precursor protein (sAPPalpha) in organotypic hippocampal slice cultures of male, postnatal day 15 mice (C57B6/SJL). Hippocampal slice cultures were treated with phosphate buffered saline (GSM26700, GSM26701, GSM26702) or 1 nM sAPPal...
ORGANISM(S): Mus musculus 
2007-10-10 | E-GEOD-1555 | biostudies-arrayexpress
ProteomicsImpaired presynaptic proteostasis in the initial stages of amyloid beta proteotoxicity
Compromised protein homeostasis underlies accumulation of plaques and tangles in Alzheimers disease (AD); however, little is known about the early mechanisms that contribute to this accumulation. To objectively assess the impaired protein turnover at early stages of amyloid beta (Abeta) proteotoxic...
ORGANISM(S): Mus Musculus (ncbitaxon:10090) 
2020-02-24 | MSV000085004 | MassIVE
ProteomicsCSF proteomics of aducanumab treated APP-SAA triple knock-in mice
Anti-amyloid β-peptide (Aβ) immunotherapy was developed as treatment for Alzheimer’s disease to reduce and prevent amyloid plaque pathology and its downstream consequences. Efficient amyloid plaque clearance has been proven in clinical trials with Aducanumab, Lecanemab and Donanemab. At least two of...
ORGANISM(S): Mus musculus (Mouse) 
2025-08-25 | PXD061932 | Pride
Cerebrospinal fluid Mouse Diapasef Aducanumab 
UnknownAutophagy Impairment in App Knock-in Alzheimer's Model Mice.
Not available
S-EPMC9160569 | biostudies-literature
TranscriptomicsTRAP-seq of astrocytes in the APP NL-F knock-in model of ß-amyloidopathy
While mouse models of ß-amyloidopathy recapitulate aspects of Alzheimer's disease pathology, including plaque formation and synapse loss, most progress at a speed such that outcomes are studied in the mature mouse, rather than the aged mouse. Here we investigated Aß-dependent changes to astrocytes i...
ORGANISM(S): Mus musculus 
2024-03-21 | E-MTAB-13936 | biostudies-arrayexpress
UnknownThe senile plaque: Morphological differences in APP knock-in mice brains by fixatives.
Not available
S-EPMC10097081 | biostudies-literature
ProteomicsMicroglial proteomic signatures in APPPS1 and APP-KI mice
Microglial dysfunction is a key pathological feature of Alzheimer´s disease (AD), but little is known about proteome-wide changes in microglia during the course of AD pathogenesis and their consequences for microglial function. Here, we performed an in-depth proteomic characterization of microglia i...
ORGANISM(S): Mus musculus (Mouse) 
2020-06-09 | PXD016075 | Pride
Neuroinflammation Phagocytosis Alzheimer’s disease Proteomic signatures Microglia 
UnknownGeneration of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology.
Not available
S-EPMC5935712 | biostudies-literature
Sort   by:  
 Page size